Search research articles
Contact Us
Filters
Showing results (1-10 of 111) with videos related to
Page
of 12
Sort By:
The New England Journal of Medicine
|
April 14, 2016
Seamless Oncology-Drug Development
Tatiana M Prowell, Marc R Theoret, Richard Pazdur
JAMA Oncology
|
June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known Unknowns
Gideon M Blumenthal, Marc R Theoret, Richard Pazdur
The New England Journal of Medicine
|
October 8, 2021
The Drug-Dosing Conundrum in Oncology - When Less Is More
Mirat Shah, Atiqur Rahman, Marc R Theoret, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2020
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Flora Mulkey, Marc R Theoret, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
Kavita Natrajan, Megha Kaushal, Bindu George, et al.
The Lancet. Oncology
|
May 5, 2018
Anti-PD-1 antibody treatment for melanoma - Authors' reply
Julia A Beaver, Patricia Keegan, Steven Lemery, et al.
Clinical Pharmacology and Therapeutics
|
April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma
G K Raju, Karthik Gurumurthi, Reuben Domike, et al.
The New England Journal of Medicine
|
June 17, 2011
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention
Marc R Theoret, Yang-Min Ning, Jenny J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Poornima Sharma, Yvette L Kasamon, Xue Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2025
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better
Kristin M Wessel, Nicole Drezner, Stacy S Shord, et al.
Page
of 12
Search research articles
Search
Showing results (1-10 of 111) with videos related to
Sort By:
Page
of 12
The New England Journal of Medicine
|
April 14, 2016
Seamless Oncology-Drug Development
Tatiana M Prowell, Marc R Theoret, Richard Pazdur
JAMA Oncology
|
June 30, 2017
Treatment Beyond Progression With Immune Checkpoint Inhibitors-Known Unknowns
Gideon M Blumenthal, Marc R Theoret, Richard Pazdur
The New England Journal of Medicine
|
October 8, 2021
The Drug-Dosing Conundrum in Oncology - When Less Is More
Mirat Shah, Atiqur Rahman, Marc R Theoret, et al.
Journal for Immunotherapy of Cancer
|
February 29, 2020
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Flora Mulkey, Marc R Theoret, Patricia Keegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 7, 2024
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
Kavita Natrajan, Megha Kaushal, Bindu George, et al.
The Lancet. Oncology
|
May 5, 2018
Anti-PD-1 antibody treatment for melanoma - Authors' reply
Julia A Beaver, Patricia Keegan, Steven Lemery, et al.
Clinical Pharmacology and Therapeutics
|
April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Melanoma
G K Raju, Karthik Gurumurthi, Reuben Domike, et al.
The New England Journal of Medicine
|
June 17, 2011
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention
Marc R Theoret, Yang-Min Ning, Jenny J Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 5, 2023
FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
Poornima Sharma, Yvette L Kasamon, Xue Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 6, 2025
Dosage Optimization of Pediatric Oncology Products: Our Patients Deserve Better
Kristin M Wessel, Nicole Drezner, Stacy S Shord, et al.
Page
of 12